BA
NWBO

BlackRock Advisors’s Northwest Biotherapeutics, Inc. Common stock NWBO Stock Holding History

BlackRock Advisors’s Portfolio NWBO Stock Details NWBO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-7,566
Closed -$4K – 3826
2016
Q3 		$4K Hold
7,566
– – ﹤0.01% 3671
2016
Q2 		$4K Sell
7,566
-12,280
-62% -$13.1K ﹤0.01% 3696
2016
Q1 		$29K Hold
19,846
– – ﹤0.01% 3344
2015
Q4 		$64K Sell
19,846
-10,575
-35% -$50.8K ﹤0.01% 3114
2015
Q3 		$190K Buy
30,421
+562
+2% +$5.25K ﹤0.01% 2757
2015
Q2 		$296K Buy
29,859
+3,672
+14% +$32.2K ﹤0.01% 2559
2015
Q1 		$193K Buy
26,187
+5,428
+26% +$36.5K ﹤0.01% 2698
2014
Q4 		$111K Buy
20,759
+613
+3% +$3.14K ﹤0.01% 2989
2014
Q3 		$101K Buy
20,146
+5,157
+34% +$31.7K ﹤0.01% 2998
2014
Q2 		$101K Buy
+14,989
New +$95.4K ﹤0.01% 3050
2014
Q1 		– Sell
-56,241
Closed -$212K – 3706
2013
Q4 		$212K Buy
+56,241
New +$218K ﹤0.01% 2627

Other funds holding NWBO

WIM
Woodford Investment Management London, United Kingdom $310M AUM 17.41% 1-Year Est. Return
CDH
Charles D. Hyman $1.79B AUM 17.18% 1-Year Est. Return
WS
Wedbush Securities Los Angeles, California $3.88B AUM 32.38% 1-Year Est. Return
MBT
Montecito Bank & Trust Santa Barbara, California $668M AUM 24.84% 1-Year Est. Return
BIP
Brandes Investment Partners La Jolla, California $14.1B AUM 25.52% 1-Year Est. Return
Tudor Investment Corp
Tudor Investment Corp Stamford, Connecticut $53.9B AUM 29.12% 1-Year Est. Return
BW
Biegel & Waller Columbia, Maryland $179M AUM 1.6% 1-Year Est. Return
MPI
Mairs & Power Inc St Paul, Minnesota $9.79B AUM 20.6% 1-Year Est. Return

BlackRock Advisors's NWBO Position: Q4 2016 in Review

BlackRock Advisors sold out of Northwest Biotherapeutics, Inc. Common stock (NWBO) in Q4 2016, closing a stake of 7,566 shares — an estimated $4K sold.

BlackRock Advisors first reported a position in NWBO in Q4 2013 and held it in 11 quarters. The position peaked at $296K in Q2 2015. 8 funds tracked by Wall St. Rank hold NWBO as of Q4 2016.

  • BlackRock Advisors reported no remaining Northwest Biotherapeutics, Inc. Common stock position as of Q4 2016 after selling out during the quarter.
  • BlackRock Advisors sold 7,566 Northwest Biotherapeutics, Inc. Common stock shares in Q4 2016, an estimated $4K.
  • BlackRock Advisors first reported a position in Northwest Biotherapeutics, Inc. Common stock in Q4 2013 and held it in 11 quarters.
  • BlackRock Advisors's Northwest Biotherapeutics, Inc. Common stock position peaked at $296K in Q2 2015.
  • 8 funds tracked by Wall St. Rank held Northwest Biotherapeutics, Inc. Common stock as of Q4 2016.

Based on BlackRock Advisors's 13F filing for Q4 2016, filed 10 Feb 2017.